Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-DLL4 Antibody is a highly specialized monoclonal antibody target the δ-like ligand 4 within the Notch signaling axis, disruption of ligand-receptor engagement to modulate both vascular organization and tumor cell differentiation across various preclinical experimental oncology models.

| Description | Anti-DLL4 Antibody is a highly specialized monoclonal antibody target the δ-like ligand 4 within the Notch signaling axis, disruption of ligand-receptor engagement to modulate both vascular organization and tumor cell differentiation across various preclinical experimental oncology models. |
| In vivo | In pancreatic cancer xenograft models, Anti-DLL4 Antibody (10-80 mg/kg) inhibited tumor growth and nonproductive angiogenesis while mitigating liver toxicity [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | DLL4 |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 2 years, 4°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.